Assessment of a novel intra-prostate sustained release docetaxel combined with radiation treatment of prostate cancer: a canine BPH Model
BACKGROUND: Prostate cancer treatment commonly involves chemotherapy, radiation, and surgery, but systemic administration of cytotoxic agents is limited by dose-limiting toxicities. Localized delivery strategies may overcome these limitations. We evaluated the feasibility of a novel intra-prostatic docetaxel sustained-release implant (InCeRT-DTX) combined with external beam radiation therapy (EBRT) in a large animal model. METHODS: Nineteen beagle dogs with benign prostatic hyperplasia (BPH) received surgical implantation of InCeRT-DTX into the prostate. A subset also underwent a single 16 Gy dose of EBRT. Pharmacokinetics, safety, local toxicity, and therapeutic responses were assessed by serum analysis, imaging, and histopathology. RESULTS: The tolerated intra-prostatic docetaxel dose was 9 µg per cm³ of prostate volume-over 10-fold higher than the estimated dose achievable by intravenous delivery in humans. At this dose, no systemic toxicities were observed, and local effects were minimal and non-clinical. Implants alone produced negligible changes in prostate morphology; however, the combination of InCeRT-DTX with EBRT resulted in a 38-45% reduction in prostate volume. Histopathological analysis showed limited necrosis and fibrosis localized to the implant site, while increased apoptotic activity suggested apoptosis as a primary mechanism of glandular shrinkage. CONCLUSIONS: Localized delivery of docetaxel via InCeRT-DTX implants enables safe administration of high intra-prostatic doses without systemic toxicity. When combined with EBRT, this approach produces significant prostate volume reduction, indicating a synergistic therapeutic effect. These findings support the translational potential of "inside-out" chemotherapy as a novel prostate cancer treatment strategy.
Authors
- Alireza Kheirollah (ORCID: https://orcid.org/0000-0002-8235-8190)
- Dylan B. Ness (ORCID: https://orcid.org/0000-0003-2941-5050)
- Lionel D. Lewis (ORCID: https://orcid.org/0000-0003-1164-5157)
- David J. Gladstone (ORCID: https://orcid.org/0000-0002-4086-0297)
- Robert A. Cormack (ORCID: https://orcid.org/0000-0001-5553-9984)
- Srinivas Sridhar (ORCID: https://orcid.org/0000-0003-1605-0734)
- Shicheng Yang
- G. Mike Makrigiorgos
- Anthony V. D’Amico
- Armin D. Tavakkoli
- Paul L. Nguyen
- P. Jack Hoopes
- Gretchen Carpenter
Institutions
- Dartmouth College (US)
- Brigham and Women's Hospital (US)
- Dartmouth–Hitchcock Medical Center (US)
- Northeastern University (US)
- Dana-Farber Cancer Institute (US)
- Dartmouth Psychiatric Research Center (US)
- Dana-Farber Brigham Cancer Center (US)
- Dartmouth Cancer Center (US)
Publication Details
- Journal
- Prostate Cancer and Prostatic Diseases
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1038/s41391-026-01174-9
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Division of Cancer Epidemiology and Genetics, National Cancer Institute